Q
QURE
uniQure N.V. Ordinary Shares
$20.97
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of uniQure N.V. Ordinary Shares in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$4.05
P/E
—
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Before the open · Expected EPS: -$0.94
Nov 10
Posts
No posts about QURE yet.
About uniQure N.V. Ordinary Shares
uniQure N.V. is a Dutch biotechnology company that develops one-time gene therapies meant to treat rare, inherited diseases by delivering corrected genes into a patient's cells. Its lead program, AMT-130, targets Huntington's disease, a fatal inherited brain disorder that currently has no treatment that slows its progression. The company earns almost no product revenue today and funds itself through cash reserves, partnership deals, and stock sales while its therapies move through clinical trials and regulatory review.